Navigation Links
Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C
Date:8/9/2012

Follow-up research from the Pediatric Study of Hepatitis C (PEDS-C) trial reveals that children treated with peginterferon alpha (pegIFNα) for hepatitis C (HCV) display significant changes in height, weight, body mass index (BMI), and body composition. Results appearing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that most growth-related side effects are reversible with cessation of therapy. However, in many children the height-for-age score had not returned to baseline two years after stopping treatment.

In the U.S. an estimated 240,000 children have the HCV antibody and up to 100,000 have chronic HCV (Jonas, 2002). "While HCV in children is typically mild, some cases do progress to cirrhosis and liver cancer," explains lead author Maureen Jonas, Director of the Center for Childhood Liver Disease and Medical Director of the Liver Transplant Program at Boston Children's Hospital in Massachusetts. "Treatment of HCV with peginterferon and ribavirin is approved for young children and offers the most benefit while liver disease is mild. However, there are concerns about the potential side effects of peginterferon therapy in children, which is the focus of our current study."

Children between the ages of 5 to 18 years with chronic HCV were recruited for the Pediatric Study of Hepatitis C (PEDS-C), a multi-center trial of the safety of pegIFNα with and without ribavirin that took place from December 2004 through May 2006. For the present study, children were followed for an additional two years to determine if height, weight, or BMI were affected by treatment. Subjects were placed into three groups based on duration of pegIFNα therapy at 24, 48 or 72 weeks.

The study group included 107 children with a mean age of 11 years of age; 55% were male, 82% were Caucasian, and all were of normal height, weight, BMI, and body composition at baseline. While on therapy, researchers observed up to a 0.5 unit decrease in height, weight, and BMI z scores (standard deviation scores) in some participants on therapy. In the 48-week treatment group, 33% of children had a greater than 0.5 unit decrement in their height-for-age z score.

Results show that mean height-for-age z scores were slower to rebound than those for weight and BMI. The authors report that after two years following the end of treatment, mean height z scores were lower than baseline in most children who had been treated with peginterferon for 48 or 72 weeks. Physical activity and food intake among the children did not change during the study period.

"Our findings demonstrate significant effects on weight, BMI, and body composition in children treated with pegIFNα that are reversible upon cessation of treatment. A reduction in linear growth persisted even after treatment was discontinued," said Dr. Jonas. "Additional investigation of growth patterns is needed to determine long-term outcomes so that optimal timing of treatment can be determined for children with chronic HCV."


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related biology news :

1. University of Tennessee professor releases weight management product
2. Hormone in fruit flies sheds light on diabetes cure, weight-loss drug for humans
3. Infants of overweight mothers grow more slowly
4. Weight-loss clinic drop-out rates are a huge barrier to treating obesity
5. Genetic link to rapid weight gain from antipsychotics discovered
6. Weight gain induced by high-fat diet increases active-period sleep and sleep fragmentation
7. Overweight? Theres a vaccine for that
8. UC Davis study finds that above-normal weight alone does not increase the short-term risk of death
9. Low vitamin D levels linked to weight gain in some older women
10. Eating disorder behaviors and weight concerns are common in women over 50
11. Omega-3 lowers inflammation in overweight older adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2020)... , ... January 30, 2020 , ... Accelera Canada ... eye on the Canadian market, is pleased to announce that the company has opened ... since the company launched in 2017. , “We are so thrilled to now ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... care efficiency, reduce total cost of care, and limit the utilization of high-cost ... provider group headquartered in San Antonio, Texas specializes in improving care delivery for ...
(Date:1/24/2020)... ... January 24, 2020 , ... Worldwide Business with kathy ... Dr. Stanley Stanbridge and Vice President of Sales and Marketing Jeff Maier to discuss ... as sponsored content on Sunday, Jan. 26, 2020 at 5:30 p.m. EST and internationally ...
Breaking Biology News(10 mins):
(Date:2/5/2020)... ... February 04, 2020 , ... ... characterizing microbiome populations down to the strain level, has announced a new distribution ... Biome’s microbiome kits and other products to companies and research organizations in China, ...
(Date:2/3/2020)... ... February 03, 2020 , ... ... Services Firm Travel, Law Firm Travel, Technology Industry Travel and Biotech/Healthcare Industry Travel ... quarterly. Each Index illustrates the following statistics:, Average ...
(Date:1/28/2020)... , ... January 28, 2020 , ... ... be the exclusive distributor to food and beverage manufactures within North America. Both ... critical suppliers. This agreement will allow each company to pool their collective resources ...
(Date:1/28/2020)... Pa. (PRWEB) , ... January 28, 2020 , ... ... of Better Salivary Assay Kits . The new Salivary Total Human ... research. “By measuring total immunoglobulin G in saliva, researchers can extend the accuracy ...
Breaking Biology Technology: